Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors

Veronica Calvo,David Surguladze,An-Hu Li,Matthew D. Surman, Srikanth Malibhatla, Madhavarao Bandaru, Suresh Krishna Jonnalagadda, Ravi Adarasandi, Madhusudhan Velmala, Durga Rama Prasad Singireddi, Mahendar Velpuri, Bhaskar Reddy Nareddy, Visweswara Sastry, Chiranjeevi Mandati, Rambabu Guguloth, Shapi Siddiqui, Basanagoud S. Patil, Elena Chad, Jennifer Wolfley,Jennifer Gasparek,Kirsten Feldman,Matthew Betzenhauser, Brent Wiens, Mary Koszelak-Rosenblum,Guangyu Zhu,Hongwen Du,Alan C. Rigby,Mark J. Mulvihill

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS(2021)

引用 4|浏览2
暂无评分
摘要
The protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is one of the three endoplasmic reticulum (ER) transmembrane sensors of the unfolded protein response (UPR) that regulates protein synthesis, alleviates cellular ER stress and has been implicated in tumorigenesis and prolonged cancer cell survival. In this study, we report a series of 2-amino-3-amido-5-aryl-pyridines that we have identified as potent, selective, and orally bioavailable PERK inhibitors. Amongst the series studied herein, compound (28) a (R)-2-Amino-5-(4-(2-(3,5difluorophenyl)-2-hydroxyacetamido)-2-ethylphenyl)-N-isopropylnicotinamide has demonstrated potent biochemical and cellular activity, robust pharmacokinetics and 70% oral bioavailability in mice. Given these data, this compound (28) was studied in the 786-O renal cell carcinoma xenograft model. We observed dosedependent, statistically significant tumor growth inhibition, supporting the use of this tool compound in additional mechanistic studies.
更多
查看译文
关键词
PERK,UPR,Kinase,Inhibitor,Orally bioavailable,786-O cell,Efficacy,Cancer,Structure-activity-relationships (SAR)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要